Literature DB >> 19246019

Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis.

Evan W Orenstein1, Sanjay Basu, N Sarita Shah, Jason R Andrews, Gerald H Friedland, Anthony P Moll, Neel R Gandhi, Alison P Galvani.   

Abstract

Multidrug-resistant (MDR) tuberculosis is a growing clinical and public-health concern. To evaluate existing evidence regarding treatment regimens for MDR tuberculosis, we used a Bayesian random-effects meta-analysis of the available therapeutic studies to assess how the reported proportion of patients treated successfully is influenced by differences in treatment regimen design, study methodology, and patient population. Successful treatment outcome was defined as cure or treatment completion. 34 clinical reports with a mean of 250 patients per report met the inclusion criteria. Our analysis shows that the proportion of patients treated successfully improved when treatment duration was at least 18 months, and if patients received directly observed therapy throughout treatment. Studies that combined both factors had significantly higher pooled success proportions (69%, 95% credible interval [CI] 64-73%) than other studies of treatment outcomes (58%, 95% CI 52-64%). Individualised treatment regimens had higher treatment success (64%, 95% CI 59-68%) than standardised regimens (54%, 95% CI 43-68%), although the difference was not significant. Treatment approaches and study methodologies were heterogeneous across studies. Many important variables, including patients' HIV status, were inconsistently reported between studies. These results underscore the importance of strong patient support and treatment follow-up systems to develop successful MDR tuberculosis treatment programmes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19246019     DOI: 10.1016/S1473-3099(09)70041-6

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  207 in total

Review 1.  A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis.

Authors:  Christopher Fitzpatrick; Katherine Floyd
Journal:  Pharmacoeconomics       Date:  2012-01       Impact factor: 4.981

Review 2.  Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis.

Authors:  Karen R Jacobson; Dylan B Tierney; Christie Y Jeon; Carole D Mitnick; Megan B Murray
Journal:  Clin Infect Dis       Date:  2010-07-01       Impact factor: 9.079

3.  Outcomes of multidrug-resistant tuberculosis among binational cases in El Paso, Texas.

Authors:  Gustavo Ferrer; Carlos Acuna-Villaorduna; Miguel Escobedo; Esteban Vlasich; Manuel Rivera
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

4.  Factors affecting treatment outcomes in drug-resistant tuberculosis cases in the Northern Cape, South Africa.

Authors:  E Elliott; H R Draper; P Baitsiwe; M M Claassens
Journal:  Public Health Action       Date:  2014-09-21

Review 5.  Surgical treatment of drug-resistant tuberculosis.

Authors:  Russell R Kempker; Sergo Vashakidze; Nelly Solomonia; Nino Dzidzikashvili; Henry M Blumberg
Journal:  Lancet Infect Dis       Date:  2012-02       Impact factor: 25.071

Review 6.  Updated diagnosis and treatment of childhood tuberculosis.

Authors:  Shou-Chien Chen; Kwo-Liang Chen; Kou-Huang Chen; Shun-Tien Chien; Kow-Tong Chen
Journal:  World J Pediatr       Date:  2013-02-07       Impact factor: 2.764

7.  Impact of the human immunodeficiency virus on early multidrug-resistant tuberculosis treatment outcomes in Botswana.

Authors:  J Hafkin; C Modongo; C Newcomb; E Lowenthal; R R MacGregor; A P Steenhoff; H Friedman; G P Bisson
Journal:  Int J Tuberc Lung Dis       Date:  2013-01-14       Impact factor: 2.373

8.  Implementation of genotype MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa.

Authors:  Karen R Jacobson; Danie Theron; Emily A Kendall; Molly F Franke; Marinus Barnard; Paul D van Helden; Tommie C Victor; Elizabeth M Streicher; Megan B Murray; Robin M Warren
Journal:  Clin Infect Dis       Date:  2012-10-22       Impact factor: 9.079

9.  Genotypic drug resistance using whole-genome sequencing of Mycobacterium tuberculosis clinical isolates from North-western Tanzania.

Authors:  Benson R Kidenya; Stephen E Mshana; Daniel W Fitzgerald; Oksana Ocheretina
Journal:  Tuberculosis (Edinb)       Date:  2018-02-21       Impact factor: 3.131

10.  Multidrug-resistant tuberculosis: Treatment and outcomes of 93 patients.

Authors:  Sarah K Brode; Robert Varadi; Jane McNamee; Nina Malek; Sharon Stewart; Frances B Jamieson; Monica Avendano
Journal:  Can Respir J       Date:  2014-12-10       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.